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n recent years, the volume of data 
generated from all aspects of our lives 
has been increasing, in parallel with 
the sophistication of analytical 
techniques used to process this data. This 
shift toward a ‘data-driven’ society has the 
potential to yield insights that can benefit 
many sectors of public life, but it has also 
prompted concerns related to privacy. A 
recent report by the Royal Society on data 
management and use [1] is a recognition that 
the fast pace of all areas of data growth 
requires careful consideration.  
In the field of healthcare research, an area 
generating large amounts of highly unique 
data about individuals is that of genome 
sequencing and genomics. Sharing of genome 
sequence data has the potential to improve 
our understanding of diseases, which can, in 
turn, improve diagnostics, treatment and 
integration of personalised medicine into 
standard healthcare practices. However, the 
difficulties associated with maintaining 
privacy of this data are significant. These 
challenges demand a need for policies that 
will encourage innovation and scientific 
progress for the collective benefit of all 
whilst minimizing the level of risk to the 
individual.  
This short article will explore the potential 
advantages and risks of using genomic data 
in medical research, and it will suggest policy 
approaches to address these challenges. 
 
 
 
What is genomics and how can it be used for 
healthcare? 
The DNA of all organisms is composed of a 
long sequence of DNA nucleotides – A, C, T 
and G – that together form a unique code. 
Through genome sequencing, scientists can 
determine the order of these letters in an 
individual organism. All humans have the 
same nucleotide letter for most positions in 
the genome, but they differ at a few positions 
which are termed ‘variants’. While most 
variants in the genome do not impact our 
physiology, some can cause disease. 
Knowledge of these variants can be useful for 
informing treatment, as well as for providing 
timely diagnoses. Many of these disease-
causing variants are rare, meaning that they 
are not observed at high rates in the general 
population. As such, genomic analysis 
requires large datasets comprised of many—
typically thousands—of genome sequences, 
so researchers have enough statistical power 
to detect such variants. Luckily, the cost of 
sequencing a genome has plummeted in 
recent years, and therefore many individuals 
can be sequenced synchronously for minimal 
costs. Nonetheless, data sharing, which is 
simply the combining of different smaller 
datasets generated in different research 
centres, can help produce the large datasets 
required. It can also increase efficient 
interpretation of the same variants across 
different research centres, reduce the risk of 
misdiagnosis, and improve the reliability of 
diagnoses [2]. Taken together, data sharing 
can be of a direct benefit to patients living 
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with rare diseases, and the UK has adopted 
several policies to encourage further data 
pooling [3]. Genomics England is leading a 
movement to adopt genomic testing as an 
integrated part of routine clinical care in the 
NHS, and the ongoing 100,000 Genomes 
Project aims to set up a genomic medicine 
service for the NHS in the coming decades 
[4].  
Concerns and Risks 
We have seen that the collection and sharing 
of genomic data has the potential to bring 
advances in scientific understanding and 
healthcare. However, there are some 
concerns associated with this. 
First, guaranteeing the privacy of individual-
level genomic data can be challenging. Data 
shared between research groups is typically 
‘de-identified’, meaning that any personally 
identifiable information (PII) must be 
removed from the dataset before genomic 
data can be shared with other research 
groups. While PII most obviously includes 
information like name, date of birth and home 
address, other information, such as a post 
code, county or even ethnicity, could be 
combined with other PII to identify an 
individual, particularly those with rare 
diseases. In the case of patients with these 
diseases, there is a concern that a breach of 
confidentiality of this information could place 
them at risk of being subject to discrimination 
and/or stigmatisation. However, the de-
identification of data could limit the ability of 
researchers to contact an individual in the 
future, for example if they are thought to 
have increased risk of a disease [2].  This 
can be circumvented by using ‘coded data,’ 
so individuals can still be linked to their 
genomic data and identification can occur if 
required, but the code is kept in a secure 
environment. However, it has been suggested 
that DNA can never be completely 
anonymised due to the inherent uniqueness of 
the genetic identity [5].  Current legislation 
does protect and regulate the sharing of 
personally identifiable data, but there is a 
lack of consensus over the appropriate level 
of safeguarding for genomic data to minimize 
privacy risks.  
A concern for the collection of genome data 
is how to obtain consent for its usage. An 
individual may consent for their own personal 
genome being sequenced and the data 
released, but this can also give indirect 
information about family members, and to a 
lesser extent, members of the same ethnic 
group and population [1, 6]. Therefore, some 
question whether a genome sequence can be 
‘owned’ and consequently whether one 
individual can consent to its use. It is also 
difficult to consent to all the possible future 
uses of the data. Both data analysis and 
genomics are rapidly advancing fields, and it 
may not be possible to foresee all future 
possibilities. A ‘broad consent’ model permits 
use of the data for an unspecified range of 
future research in recognition of these 
difficulties, but it is important that individuals 
understand what this consent means in 
practice.  
Suggested policy approaches 
Several different sources have argued for 
new regulatory bodies to address the 
challenges of a changing genomic medicine 
landscape. The Science and Technology 
Committee recently launched an inquiry into 
genomics and genome editing, where 
suggestions were made that a new body, 
similar to the Human Genetics Commission 
which existed up to 2012, should be formed 
[7]. In her 2016 annual report ‘Generation 
Genome’, Dame Sally Davies recommends 
that government public engagement with 
genomics should be increased with the 
creation of a new National Genomics Board 
[5]. This approach will help to ensure that 
progression will be monitored and 
investigation into any potential harm is 
carried out.  
A consensus for how genomic data will be 
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confidentially treated should be reached. If 
successful, lessons can be taken from the 
100,000 Genomes Project and applied to 
other projects. They have created a secure 
data governance system for storage and 
access of sensitive patient data, where de-
identified data is analysed in a monitored 
environment. Researchers need to apply to 
access the de-identified data which can only 
be approved if the purpose is deemed 
reasonable. In addition, the database of 
Genotypes and Phenotypes, which is a 
National Institutes sponsored repository of 
large-scale genetic and clinical datasets, has 
a rigorous application process for 
annonymised data and requires research 
institutes to provide secure data storage that 
aligns with their guidelines [8]. In agreement 
with this, a report by the Nuffield Council on 
Bioethics also makes the following 
recommendations; that privacy breaches 
must be reported to affected individuals, that 
criminal penalties should apply for misuse of 
data, and that access to data is restricted to 
researchers that are subject to institutional 
oversight [3].   
Another consideration is the importance of 
cultivating public trust in any genome 
sequencing project. As in any area of human 
subjects research, the security of data 
storage must be made fully transparent to 
those involved in a study, and researchers 
should acknowledge that privacy cannot be 
completely guaranteed. An example of a 
healthcare data project that failed because it 
did not cultivate public trust was the NHS’s 
care.data program. The purpose was to 
extract data from GP practices and link it with 
that from hospitals, to improve treatments 
and patient care. However, it was stopped in 
2016 after concerns over data privacy 
weren’t fully addressed or communicated to 
patients [9,10]. Despite extensive patient 
communication and public dialogue, there 
remains confusion over the concept of 
anonymised and pseudo-anonymised data in 
the 100,000 genomes project [11]. This 
highlights the importance of maintaining a 
clear dialogue with the public. Finally, new 
uses for genomic data emerge every year, 
and policymakers should consider how 
obtaining informed consent at each stage of 
these new developments could increase an 
individual’s knowledge and ownership over 
the use of their data. 
Conclusions 
It is expected that as genome sequencing and 
genomic testing becomes more commonplace 
in research and healthcare, a shift in the 
policy landscape will be required to manage 
the associated risks. It is important that 
scientific progress in this area can continue, 
but in a secure environment that people trust. 
Public participation is vital for the success of 
future genomic research projects, and their 
promise to deliver transformative genomic 
medicine.  
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